Chirag Rajkumar Kopp

Chirag Rajkumar Kopp

Auto-generated profile, based on publicly available information

Chirag Rajkumar Kopp

Clinical Immunology and Rheumatology Division, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2023 in Clinical Endocrinology
Verified
Journal Article
Closed access
DPDhrumil Deveshkumar Patel
Dhrumil Deveshkumar Patel
SBSamiksha Bhattacharjee
Samiksha Bhattacharjee
APAvaneesh Kumar Pandey
Avaneesh Kumar Pandey
CKChirag Rajkumar Kopp
Chirag Rajkumar Kopp
AAAbhiram G. Ashwathanarayana
Abhiram G. Ashwathanarayana
MDManjunath Havalappa Dodamani
Manjunath Havalappa Dodamani

24 July 2023 in Lupus
Verified
Journal Article
Closed access
CKChirag Rajkumar Kopp
Chirag Rajkumar Kopp
CPChandra Bhushan Prasad
Chandra Bhushan Prasad
SNShankar Naidu
Shankar Naidu
VSVishal Sharma
Vishal Sharma
DMDurga Prasanna Misra
Durga Prasanna Misra
ASAman Sharma
Aman Sharma
Background: Neurological involvement can occur in systemic lupus erythematosus (SLE) due to co-existing neuromyelitis optica spectrum disorder (NMOSD). The symptoms can mimic those of neuropsychiatric manifestations of SLE. Pathogenic anti-aquaporin-4 (AQP4) antibodies, commonly found in NMOSD, are responsible for the neuroinflammatory response and secondary demyelinating lesions. These anti-AQP4 antibodies can be the drivers of neuroinflammatory process in SLE patients, which is distinct from the immunopathogenesis seen in traditional neuropsychiatric SLE. The clinical course is often a relapsing one and is managed differently. In this review, we describe and outline the clinical course and outcomes of AQP4+ NMOSD/SLE overlap cases. Methods: To investigate the co-existence of SLE with AQP4+NMOSD, we conducted a systematic review of individual patient data from case reports and case series reported in major databases. The study extracted clinic-demographic features, imaging and laboratory profiles, treatment approaches, and outcomes of these patients. Inclusion criteria for the review required patients to have positivity for AQP4 or NMO in the blood and/or cerebrospinal fluid (CSF) and exhibit at least one manifestation of both NMOSD and SLE. Results: In this overlap between SLE and AQP4+NMOSD, a high female preponderance was observed, with 42 out of 46 patients (91.3%) being female. Nearly half of the NMOSD cases (47.8%) had onset after lupus, with a median of 5 years between the two diagnoses. Hematological manifestations were seen in the majority of patients (63%), as well as longitudinally extensive transverse myelitis (87%), and brainstem involvement on imaging (29.6%). Cerebrospinal fluid analysis showed a dominantly lymphocytic pleocytosis, with oligoclonal bands being reported scarcely. Although cyclophosphamide was the most common steroid sparing agent used for maintenance, robust evidence for both efficacy and safety in AQP4+NMOSD is available for mycophenolate mofetil, azathioprine, and rituximab. The majority of reported cases showed a relapsing course, while one patient had a monophasic course. Conclusion: AQP4+NMOSD in SLE patients is a relapsing and neurologically disabling disorder that can mimic neuropsychiatric manifestations, frequently occurs after the onset of lupus or may predate, responds to immunosuppressants, and necessitates indefinite treatment.


15 September 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
SMShubhra Mishra
Shubhra Mishra
ASAnupam Kumar Singh
Anupam Kumar Singh
CKChirag Kopp
Chirag Kopp
AJAnuraag Jena
Anuraag Jena
VSVishal Sharma
Vishal Sharma
To the Editors,A 45-year-old female presented in January 2021 with bloody diarrhea for 2 weeks (7-8 bowel movements/day). She had been diagnosed with left-sided ulcerative colitis 7 years back and was on maintenance therapy with oral mesalamine (3.6 gram/day) and azathioprine (100 mg/day). Sigmoidoscopy revealed hyperaemia, friability, and deep ulcerations (complete Mayo score, 10). Intravenous methylprednisolone of 60 mg/day was initiated, but stool frequency remained high (8/day) after 3 days of steroids. Because patient could not afford biologics, 10 mg of oral tofacitinib twice a day was started on the fifth day. The chest roentgenogram and Mantoux test done prior to starting tofacitinib were normal. She responded by the fourth...

23 September 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
CKChirag Rajkumar Kopp
Chirag Rajkumar Kopp
SSShefali Khanna Sharma
Shefali Khanna Sharma
VKVenkata Subramanian Krishnaraju
Venkata Subramanian Krishnaraju
ASAshwani Sood
Ashwani Sood
RKRajender Kumar
Rajender Kumar
SJSanjay K. Jain
Sanjay K. Jain
To assess chemokine receptor CXCR4 expression in lung parenchyma and on peripheral immune cells in systemic sclerosis-related interstitial lung disease (SSc-ILD) patients. SSc-ILD patients underwent 68Ga- CPCR4 Trifluoroacetate positron emission tomography (PET) scan, SUVmean in different lung regions and architecturally abnormal areas, and receiver operating characteristic (ROC) curves were analyzed. CXCR4 expression on peripheral immune cells using flow cytometer was studied and correlated with the different lung regions. In addition, subset analysis of CXCR4 expression by clinical subset (early, progressive, stable), ILD pattern and anti-Scl-70 positivity were done. On PET, SSc-ILD patients showed higher median SUVmean uptake of CXCR4 in the whole lung (0.56; p< 0.0001), different lung regions and architecturally abnormal areas than controls. Highest area under curve (AUC) were observed in dorsobasal regions (AUC-0.91; p< 0.0001) and reticular with architecturally distorted areas (AUC-0.95; p< 0.0001). Progressive subset had higher whole lung median SUVmean (0.73) than early (0.49; p< 0.0001) and stable (0.45; p< 0.0001) subsets, and AUC than early and stable subsets. Usual interstitial pneumonia pattern ILD showed higher CXCR4 uptake compared with non-specific interstitial pneumonia (p= 0.0032). Additionally, a trend for higher uptake was noted in anti-Scl70 positive patients as compared with anti-Scl70 negative ones. SSc-ILD patients had higher CD4+CXCR4+T cells (p= 0.0003), and CD8+CXCR4+T cells (p= 0.0013), and showed moderate to strong association on correlation with the lung parenchymal regions. In SSc-ILD, CXCR4 expression is upregulated in both lung parenchyma and peripheral T cells, significantly in progressive and UIP subsets. CXCR4 expression is a potential tool for activity assessment and prognostication.

24 August 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
CKChirag Rajkumar Kopp
Chirag Rajkumar Kopp
GNGsrsnk Naidu
Gsrsnk Naidu
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
PDPrateek Deo
Prateek Deo
RJRoopesh Sai Jakulla
Roopesh Sai Jakulla
ASAman Sharma
Aman Sharma